3 Tertiary Hospital, Paediatric Care and Molecular Diagnostics Stocks With a Strong Future Roadmap: Global Health, Rainbow Children’s Medicare and Molbio Diagnostics
- October 21, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Global Health, Rainbow Children’s Medicare and Molbio Diagnostics: ROE of 14.1% to 16.9% and FY22 to FY26 revenue CAGR of 15.2% to 19.6%. Prices as of 20 Oct 2026.
Quick Answer
The three specialty healthcare stocks to watch are Global Health, Rainbow Children’s Medicare and Molbio Diagnostics. Their return on equity ranges from 14.1% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.2% to 19.6%. Rainbow Children’s Medicare has the highest return on equity at 16.9%, while Global Health has the fastest revenue growth at 19.6% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Specialty healthcare stocks focus on areas of medicine where trained doctors, branded facilities and technology give a lasting edge. Global Health, Rainbow Children’s Medicare and Molbio Diagnostics cover a tertiary-care hospital group, a paediatric and maternity network and a molecular diagnostics maker.
This list covers three specialty healthcare stocks with complete current figures: Global Health, Rainbow Children’s Medicare and Molbio Diagnostics. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Specialty Healthcare Stocks?
Specialty healthcare stocks are listed companies that concentrate on a defined field such as complex surgery, child and women’s care or advanced testing. A narrow focus helps them build a reputation, attract expert doctors and earn higher revenue from each patient or test.
Specialty Healthcare Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Global Health | 1,238.1 | 33,277 | 60.3 | 59.6 | 14.1 | 0.30 |
| Rainbow Children’s Medicare | 1,236 | 12,554 | 43.2 | 59.6 | 16.9 | 0.54 |
| Molbio Diagnostics | 1,434.8 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
On valuation, Rainbow Children’s Medicare trades at a P/E below the industry P/E, while Global Health and Molbio Diagnostics trade above it, which reflects the growth the market already expects. Readers comparing specialty healthcare stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Specialty Healthcare Stocks Have a Strong Roadmap in India?
Specialty healthcare stocks have a strong roadmap in India because patients are willing to travel and pay for expert care, and doctors and technology are concentrating in specialised centres.
- Expert care. Complex procedures such as cardiac, transplant and neonatal care draw patients to specialist centres.
- Cluster model. Adding hospitals near existing ones builds referrals and lowers launch costs.
- Molecular testing. Rapid, accurate diagnostics are becoming standard in clinical decisions.
Why Global Health Features Among These Specialty Healthcare Stocks
Among the specialty healthcare stocks on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.
In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%.
Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6.
Roadmap: Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.
What to watch: Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.
Why Rainbow Children’s Medicare Features Among These Specialty Healthcare Stocks
Among the specialty hospital shares on this list, Rainbow Children’s Medicare operates paediatric, neonatal and maternity hospitals under the Rainbow Children’s Hospital and BirthRight by Rainbow brands, with clusters in Hyderabad, Bengaluru, Chennai and Delhi NCR.
The company has a return on equity of 16.9%, a debt to equity ratio of 0.54 and a market capitalisation of Rs 12,554 crore. The stock trades at a P/E of 43.2, below the industry P/E of 59.6.
Revenue rose from Rs 993 crore in FY22 to Rs 1,747 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 139 crore in FY22 to Rs 282 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 29.4% year on year to Rs 483 crore, while net profit rose 16.2% to Rs 62.5 crore.
Roadmap: The company adds hospitals in a cluster model, so each new site draws referrals from nearby facilities. Its focus on child and women’s healthcare is a defined niche where few organised competitors operate at scale, which helps both pricing and brand recall.
What to watch: Monitor how fast new clusters in Delhi NCR and other regions reach breakeven.
Why Molbio Diagnostics Features Among These Specialty Healthcare Stocks
Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Global Health vs Rainbow Children’s Medicare vs Molbio Diagnostics on Key Financials
The table below sets the three specialty healthcare stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Global Health | 2,206 | 4,509 | 19.6% | 554 | 12.3% |
| Rainbow Children’s Medicare | 993 | 1,747 | 15.2% | 282 | 16.1% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
Rainbow Children’s Medicare posts the highest return on equity in this group at 16.9%. Global Health combines the largest FY26 revenue at Rs 4,509 crore with the fastest revenue growth, a 19.6% compound annual rate. A useful habit with specialty healthcare stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Specialty Healthcare Stocks
Every theme carries risks that deserve a check before any decision. For these specialty healthcare stocks, the main points are: Long-term specialty hospital shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- New site ramp-up. Fresh hospitals take time to reach breakeven.
- Regulatory approvals. Test kits and devices depend on approval timelines in different markets.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter specialty healthcare stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Specialty Healthcare Stocks
Specialty healthcare stocks suit investors who prefer focused businesses with a defined moat. Global Health, Rainbow Children’s Medicare and Molbio Diagnostics each stand out in their own corner of care and diagnostics. Based on the 20 October 2026 close, Global Health trades at Rs 1,238.1, Rainbow Children’s Medicare at Rs 1,236 and Molbio Diagnostics at Rs 1,434.8. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these specialty healthcare stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track specialty healthcare stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are specialty healthcare stocks?
Ans. Specialty healthcare stocks are listed companies that concentrate on a defined field such as complex surgery, child and women’s care or advanced testing. A narrow focus helps them build a reputation, attract expert doctors and earn higher revenue from each patient or test. This list looks at three of them, Global Health, Rainbow Children’s Medicare and Molbio Diagnostics, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which specialty healthcare stocks are covered in this list?
Ans. This list covers Global Health, Rainbow Children’s Medicare and Molbio Diagnostics. Based on the 20 October 2026 close, Global Health traded at Rs 1,238.1, Rainbow Children’s Medicare at Rs 1,236 and Molbio Diagnostics at Rs 1,434.8. Their return on equity ranges from 14.1% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.2% to 19.6%.
Why do specialty healthcare stocks have a strong future roadmap in India?
Ans. Specialty healthcare stocks have a strong roadmap in India because patients are willing to travel and pay for expert care, and doctors and technology are concentrating in specialised centres. The main drivers are as follows. Expert care. Complex procedures such as cardiac, transplant and neonatal care draw patients to specialist centres. Cluster model. Adding hospitals near existing ones builds referrals and lowers launch costs. Molecular testing. Rapid, accurate diagnostics are becoming standard in clinical decisions. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Global Health performed financially?
Ans. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.
How has Rainbow Children’s Medicare performed financially?
Ans. Revenue rose from Rs 993 crore in FY22 to Rs 1,747 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 139 crore in FY22 to Rs 282 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 29.4% year on year to Rs 483 crore, while net profit rose 16.2% to Rs 62.5 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.54 and a market capitalisation of Rs 12,554 crore. The stock trades at a P/E of 43.2, below the industry P/E of 59.6. Looking ahead, the company adds hospitals in a cluster model, so each new site draws referrals from nearby facilities. Its focus on child and women’s healthcare is a defined niche where few organised competitors operate at scale, which helps both pricing and brand recall.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What risks should investors check before buying specialty healthcare stocks?
Ans. Investors should check a few risks before buying specialty healthcare stocks. New site ramp-up. Fresh hospitals take time to reach breakeven. Regulatory approvals. Test kits and devices depend on approval timelines in different markets. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of specialty healthcare stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.